Thyrocare Technologies vs Peers
- Market cap
- ₹8,222 crore
- P/E
- 46.6
- P/B
- 14.04
- ROE
- 28.8%
- Dividend yield
- 1.36%
Thyrocare Technologies ranks 4th by market capitalisation among 8 Healthcare Service Provider companies tracked by ATS. Its largest peers are Dr. Lal Path Labs, Vijaya Diagnostic Centre and Metropolis Healthcare. Its P/E of 46.6 compares with a peer median of 56.0.
Thyrocare Technologies vs Healthcare Service Provider peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 1,950.50 | -0.70% | 32,569 | 60.1 | 12.99 | 21.6% | +12.5% |
| Vijaya Diagnostic Centre | 1,475.00 | +0.57% | 15,177 | 81.0 | 15.86 | 19.7% | +12.5% |
| Metropolis Healthcare | 545.00 | -1.38% | 11,299 | 56.0 | 7.47 | 13.4% | +12.5% |
| Thyrocare Technologies | 516.55 | -2.50% | 8,222 | 46.6 | 14.04 | 28.8% | — |
| Nephrocare Health Services | 643.15 | +1.36% | 6,453 | 75.8 | 5.78 | 9.0% | +12.5% |
| 3B Blackbio Dx | 1,640.70 | +4.16% | 1,408 | 25.4 | 4.34 | 20.2% | +12.5% |
| Health X Platform | 284.15 | -0.28% | 904 | 22.5 | 1.41 | 0.2% | +12.5% |
| Gaudium IVF and Women Health | 107.50 | -1.63% | 782 | 33.7 | 3.20 | 16.4% | +12.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.
Thyrocare Technologies peer comparison — frequently asked questions
Who are Thyrocare Technologies' competitors?
Thyrocare Technologies' listed peers in Healthcare Service Provider include Dr. Lal Path Labs, Vijaya Diagnostic Centre, Metropolis Healthcare, Nephrocare Health Services, 3B Blackbio Dx and Health X Platform, ranked here by market capitalisation.
How does Thyrocare Technologies' P/E compare with its peers?
Thyrocare Technologies trades at a P/E of 46.6, against a median of 56.0 across the 7 Healthcare Service Provider peers shown.
Which is the largest company among Thyrocare Technologies' peers?
By market capitalisation, the largest company in the group is Dr. Lal Path Labs at ₹32,569 crore, against ₹8,222 crore for Thyrocare Technologies.
Same Data For Peers
Trade Thyrocare Technologies With ATS
Track THYROCARE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.